• Publications
  • Influence
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
BACKGROUND The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's diseaseExpand
  • 2,107
  • 70
  • PDF
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-basedExpand
  • 1,000
  • 48
  • PDF
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
BACKGROUND Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS We conducted two double-blind, randomized,Expand
  • 1,214
  • 38
  • PDF
Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience
Psychiatric neurosurgery teams in the United States and Europe have studied deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) forExpand
  • 576
  • 34
  • PDF
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
BACKGROUND Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIAExpand
  • 293
  • 23
  • PDF
Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder
Deep brain stimulation (DBS) of the anterior limb of the internal capsule has been shown to be beneficial in the short term for obsessive–compulsive disorder (OCD) patients who exhaust conventionalExpand
  • 493
  • 19
  • PDF
Executive dysfunction and apathy predict functional impairment in Alzheimer disease.
OBJECTIVE The purpose of this study was to examine the extent to which executive cognitive dysfunction and frontally-mediated behavioral disturbances are associated with functional impairment inExpand
  • 275
  • 17
Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly
Both amyloid‐β (Aβ) deposition and brain atrophy are associated with Alzheimer's disease (AD) and the disease process likely begins many years before symptoms appear. We sought to determine whetherExpand
  • 264
  • 12
  • PDF
Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder
Correction to: Neuropsychopharmacology (2006) 31, 2384–2393. doi:10.1038/sj.npp.1301165 In addition to the research support from Medtronic Inc. already noted, the authors wish to also acknowledgeExpand
  • 164
  • 11
  • PDF
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD). Expand
  • 241
  • 10
  • PDF